Efficacy and safety of pyrotinib-based regimens in patients with HER2-positive stage III/IV breast cancer: a real-world retrospective study in China.

ABSTRACT:

Background

Data from multiple clinical trials have shown that pyrotinib has demonstrated significant efficacy and acceptable tolerability in patients with HER2-positive advanced breast cancer (BC). However, the short time to market in China limits our comprehensive understanding of the drug's long-term efficacy and potential adverse events (AEs) from the drug. Therefore, this study analyzed the clinical efficacy and safety of pyrotinib-based regimens in a real-world database.

Materials and methods

This study retrospectively analyzed patients with HER2-positive stage III/IV BC who were treated with pyrotinib-based regimens from October 2018 to October 2022 at the Affiliated Tumor Hospital of Guangxi Medical University. Tumor assessments were based on RECIST 1.1, and AEs were

SUBMITTER: Zhi L 

PROVIDER: S-EPMC12810360 | biostudies-literature | 2026

REPOSITORIES: biostudies-literature